Predicting tumor spread using a radiomics model

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to validate a radiomics model that predicts tumor metastasis patterns based on the 'soil-seed' theory. The model focuses on common metastasis sites such as the brain for lung cancer, liver for colorectal cancer, and lungs for breast cancer. By analyzing imaging data and patient characteristics, the study seeks to enhance early diagnosis and treatment strategies for metastatic cancer. The research will involve patients with advanced cancer who have not yet shown signs of metastasis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. ECOG performance status score 0-2;
2. Histologically or cytologically confirmed stage III-IV NSCLC;
3. If the baseline pathology is adenocarcinoma, driver gene testing (at least EGFR/ALK/ROS1/KRAS/MET) should be performed;
4. Complete imaging data of baseline stage (contrast-enhanced MR For lung cancer, contrast-enhanced MR/CT for colorectal cancer, and chest CT for breast cancer);
5. No target organ metastasis on baseline imaging (no brain/liver/lung metastasis for lung cancer/colorectal cancer/breast cancer, respectively);
6. Patients received at least one systemic therapy (chemotherapy, targeted therapy, immunotherapy, etc.) and received regular follow-up;
7. Regular follow-up during and after treatment;
8. Life expectancy ≥6 months;

Exclusion Criteria:

1. Patients with indeterminate pathological type;
2. Patients without baseline imaging data before treatment;
3. Baseline imaging examination showed that the corresponding target organ had metastasis (lung cancer/colorectal cancer/breast cancer corresponding to brain/liver/lung metastasis);
4. patients who cannot or refuse to receive regular imaging follow-up;
5. Combined history of other malignant tumors;
6. Medical examination or clinical findings or other uncontrollable conditions that the investigator considers may interfere with the results or increase the risk of treatment complications for the patient; ,
7. Lactating or pregnant women;
8. Receiving other long-term medications that may affect disease progression as assessed by a physician.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting
• Fudan University Shanghai Cancer Center
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Xiao Chu
• Email: chuxiao@sibs.ac.cn
• Phone: 15821383376

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Luvometinib plus Anlotinib in KRAS-mutated NSCLC

  This study tests whether the combination of luvometinib and anlotinib helps people with KRAS-mutated metastatic non-small cell lung cancer who have tried prior treatments.

  Recruiting Phase 2 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Shanghai, Shanghai Municipality · NCT07562581

• Gefitinib, trametinib, disulfiram, and sunitinib added to standard chemotherapy for metastatic osteosarcoma

  This study tests whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy helps people with newly diagnosed metastatic osteosarcoma.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07477457

• Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer

  This registry will see if adding local treatments such as radiation or surgery to standard systemic therapy helps people with oligo‑metastatic or oligo‑recurrent cervical cancer live longer or avoid progression.

  Recruiting Tata Memorial Hospital · Mumbai, Maharashtra · NCT07400809

• Fast detection of cancer in sentinel lymph nodes using a new NIR-II fluorescent probe.

  This test applies a new near-infrared (NIR-II) fluorescent probe to freshly removed sentinel lymph nodes to quickly tell adults with breast cancer whether the cancer has spread there.

  Recruiting Yunnan Cancer Hospital · Kunming, Yunnan · NCT07154563

• Two-point versus four-point cervical methylene blue injections for sentinel lymph node mapping in stage I endometrial cancer

  This test checks whether using four cervical methylene blue injections instead of the usual two helps surgeons find sentinel lymph nodes in people with newly diagnosed stage I endometrial cancer who are having surgery.

  Recruiting at 2 sites Dokuz Eylul University · Ankara and 1 other locations · NCT07040657

• Real-world look at SKB264 in HER2-negative breast cancer that has come back or spread

  This real-world study tests sacituzumab tirumotecan (SKB264) alone or with others in adults with recurrent or metastatic HER2-negative breast cancer.

  Recruiting at 12 sites Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Hefei, Anhui and 18 other locations · NCT06993506

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.